Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Sell
45
CSTL Quote, Financials, Valuation and Earnings
Last price:
$39.32
Seasonality move
:
-14.47%
Day range:
$38.68 - $40.71
52-week range:
$14.59 - $42.18
Dividend yield:
0%
P/E ratio:
30.24x
P/S ratio:
3.36x
P/B ratio:
2.46x
Volume:
334.2K
Avg. volume:
362.5K
1-year change:
20.23%
Market cap:
$1.1B
Revenue:
$332.1M
EPS (TTM):
-$0.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$75.9M | -$0.45 | -13.73% | -49.97% | $43.75 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$207.8M | $1.63 | 5.42% | 138.16% | $109.25 |
|
CRMD
CorMedix, Inc.
|
$117.4M | $0.57 | 200.36% | 90.44% | $17.71 |
|
CTSO
CytoSorbents Corp.
|
$9.7M | -$0.07 | 51.05% | -41.38% | $4.92 |
|
DCTH
Delcath Systems, Inc.
|
$24.4M | $0.08 | 25.47% | 66.05% | $22.33 |
|
STRR
Star Operating Cos., Inc.
|
$16.8M | -$0.76 | 50.04% | -65.48% | $12.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$39.34 | $43.75 | $1.1B | 30.24x | $0.00 | 0% | 3.36x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$76.28 | $109.25 | $1.7B | 46.78x | $0.00 | 0% | 1.87x |
|
CRMD
CorMedix, Inc.
|
$7.63 | $17.71 | $601.2M | 3.72x | $0.00 | 0% | 2.57x |
|
CTSO
CytoSorbents Corp.
|
$0.67 | $4.92 | $42.1M | -- | $0.00 | 0% | 1.20x |
|
DCTH
Delcath Systems, Inc.
|
$10.34 | $22.33 | $365.1M | 1,188.51x | $0.00 | 0% | 4.93x |
|
STRR
Star Operating Cos., Inc.
|
$10.72 | $12.00 | $36.8M | 0.75x | $0.00 | 0% | 0.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
7.37% | 0.711 | 5.59% | 6.09x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.736 | 30.7% | 2.40x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
CTSO
CytoSorbents Corp.
|
75.25% | 1.234 | 46.74% | 1.49x |
|
DCTH
Delcath Systems, Inc.
|
0.83% | 2.032 | 0.25% | 12.82x |
|
STRR
Star Operating Cos., Inc.
|
26.85% | 8.200 | 70.75% | 0.76x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$61.5M | -$6.8M | -2.54% | -2.71% | -8.19% | $7.8M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
CTSO
CytoSorbents Corp.
|
$6.7M | -$2.7M | -27.15% | -89.32% | -28.07% | -$2.5M |
|
DCTH
Delcath Systems, Inc.
|
$17.9M | -$388K | 1.56% | 1.59% | -1.89% | $4.3M |
|
STRR
Star Operating Cos., Inc.
|
$5.6M | -$866K | -2.74% | -3.67% | -3.65% | -$2.4M |
Castle Biosciences, Inc. vs. Competitors
-
Which has Higher Returns CSTL or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 10.59%. Castle Biosciences, Inc.'s return on equity of -2.71% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About CSTL or ANIP?
Castle Biosciences, Inc. has a consensus price target of $43.75, signalling upside risk potential of 11.21%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 43.22%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is CSTL or ANIP More Risky?
Castle Biosciences, Inc. has a beta of 1.060, which suggesting that the stock is 5.975% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.46%.
-
Which is a Better Dividend Stock CSTL or ANIP?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSTL or ANIP?
Castle Biosciences, Inc. quarterly revenues are $83M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Castle Biosciences, Inc.'s net income of -$501K is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while ANI Pharmaceuticals, Inc.'s PE ratio is 46.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.36x versus 1.87x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.3.36x 30.24x $83M -$501K ANIPANI Pharmaceuticals, Inc.1.87x 46.78x $227.8M $24.1M
-
Which has Higher Returns CSTL or CRMD?
CorMedix, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 49.9%. Castle Biosciences, Inc.'s return on equity of -2.71% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About CSTL or CRMD?
Castle Biosciences, Inc. has a consensus price target of $43.75, signalling upside risk potential of 11.21%. On the other hand CorMedix, Inc. has an analysts' consensus of $17.71 which suggests that it could grow by 132.17%. Given that CorMedix, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe CorMedix, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 CRMDCorMedix, Inc.4 0 0 -
Is CSTL or CRMD More Risky?
Castle Biosciences, Inc. has a beta of 1.060, which suggesting that the stock is 5.975% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock CSTL or CRMD?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or CRMD?
Castle Biosciences, Inc. quarterly revenues are $83M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Castle Biosciences, Inc.'s net income of -$501K is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while CorMedix, Inc.'s PE ratio is 3.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.36x versus 2.57x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.3.36x 30.24x $83M -$501K CRMDCorMedix, Inc.2.57x 3.72x $104.3M $108.6M
-
Which has Higher Returns CSTL or CTSO?
CytoSorbents Corp. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of -33.42%. Castle Biosciences, Inc.'s return on equity of -2.71% beat CytoSorbents Corp.'s return on equity of -89.32%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M CTSOCytoSorbents Corp.70.28% -$0.05 $36.4M -
What do Analysts Say About CSTL or CTSO?
Castle Biosciences, Inc. has a consensus price target of $43.75, signalling upside risk potential of 11.21%. On the other hand CytoSorbents Corp. has an analysts' consensus of $4.92 which suggests that it could grow by 632.74%. Given that CytoSorbents Corp. has higher upside potential than Castle Biosciences, Inc., analysts believe CytoSorbents Corp. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 CTSOCytoSorbents Corp.1 1 0 -
Is CSTL or CTSO More Risky?
Castle Biosciences, Inc. has a beta of 1.060, which suggesting that the stock is 5.975% more volatile than S&P 500. In comparison CytoSorbents Corp. has a beta of 1.320, suggesting its more volatile than the S&P 500 by 31.967%.
-
Which is a Better Dividend Stock CSTL or CTSO?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. CytoSorbents Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or CTSO?
Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than CytoSorbents Corp. quarterly revenues of $9.5M. Castle Biosciences, Inc.'s net income of -$501K is higher than CytoSorbents Corp.'s net income of -$3.2M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while CytoSorbents Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.36x versus 1.20x for CytoSorbents Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.3.36x 30.24x $83M -$501K CTSOCytoSorbents Corp.1.20x -- $9.5M -$3.2M
-
Which has Higher Returns CSTL or DCTH?
Delcath Systems, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 4.04%. Castle Biosciences, Inc.'s return on equity of -2.71% beat Delcath Systems, Inc.'s return on equity of 1.59%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M DCTHDelcath Systems, Inc.87.24% $0.02 $115.8M -
What do Analysts Say About CSTL or DCTH?
Castle Biosciences, Inc. has a consensus price target of $43.75, signalling upside risk potential of 11.21%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.33 which suggests that it could grow by 115.99%. Given that Delcath Systems, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe Delcath Systems, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 DCTHDelcath Systems, Inc.5 0 0 -
Is CSTL or DCTH More Risky?
Castle Biosciences, Inc. has a beta of 1.060, which suggesting that the stock is 5.975% more volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.664%.
-
Which is a Better Dividend Stock CSTL or DCTH?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or DCTH?
Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than Delcath Systems, Inc. quarterly revenues of $20.6M. Castle Biosciences, Inc.'s net income of -$501K is lower than Delcath Systems, Inc.'s net income of $830K. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Delcath Systems, Inc.'s PE ratio is 1,188.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.36x versus 4.93x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.3.36x 30.24x $83M -$501K DCTHDelcath Systems, Inc.4.93x 1,188.51x $20.6M $830K
-
Which has Higher Returns CSTL or STRR?
Star Operating Cos., Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 14.56%. Castle Biosciences, Inc.'s return on equity of -2.71% beat Star Operating Cos., Inc.'s return on equity of -3.67%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M STRRStar Operating Cos., Inc.23.43% $0.86 $85.6M -
What do Analysts Say About CSTL or STRR?
Castle Biosciences, Inc. has a consensus price target of $43.75, signalling upside risk potential of 11.21%. On the other hand Star Operating Cos., Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 11.94%. Given that Star Operating Cos., Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe Star Operating Cos., Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 STRRStar Operating Cos., Inc.1 1 0 -
Is CSTL or STRR More Risky?
Castle Biosciences, Inc. has a beta of 1.060, which suggesting that the stock is 5.975% more volatile than S&P 500. In comparison Star Operating Cos., Inc. has a beta of 2.711, suggesting its more volatile than the S&P 500 by 171.052%.
-
Which is a Better Dividend Stock CSTL or STRR?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Operating Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Star Operating Cos., Inc. pays out 19.54% of its earnings as a dividend. Star Operating Cos., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSTL or STRR?
Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than Star Operating Cos., Inc. quarterly revenues of $23.7M. Castle Biosciences, Inc.'s net income of -$501K is lower than Star Operating Cos., Inc.'s net income of $3.5M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Star Operating Cos., Inc.'s PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 3.36x versus 0.51x for Star Operating Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.3.36x 30.24x $83M -$501K STRRStar Operating Cos., Inc.0.51x 0.75x $23.7M $3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
